EP3261669A2 - USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA)AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS